Penumbra (NYSE:PEN) Sets New 12-Month High – Here’s Why

Penumbra, Inc. (NYSE:PEN) shares hit a new 52-week high during trading on Thursday . The company traded as high as $352.00 and last traded at $351.5470, with a volume of 1788470 shares trading hands. The stock had previously closed at $313.43.

Key Penumbra News

Here are the key news stories impacting Penumbra this week:

• Positive Sentiment: Boston Scientific agreed to acquire Penumbra for $374 per share in a cash-and-stock deal, citing strategic expansion into mechanical thrombectomy and neurovascular markets — the transaction creates a significant takeover premium that lifted investor interest. Boston Scientific announces agreement to acquire Penumbra, Inc.
• Positive Sentiment: Penumbra issued preliminary Q4 and FY2025 results/guidance showing higher-than-consensus Q4 revenue guidance (~$383.0M–$384.8M vs. $361.9M consensus) and FY revenue around $1.4B — these operational beats support the deal valuation and the company’s growth profile. Penumbra provides preliminary update on Q4 and FY2025 results
• Neutral Sentiment: Wells Fargo cut its rating to Equal Weight but left a $374 price target — the target essentially aligns with the deal price, implying limited upside beyond the acquisition terms unless a competing bid emerges. Penumbra downgraded at Wells Fargo
• Neutral Sentiment: Market commentary and earnings-estimate revisions note strong recent volume and a large one-day surge; analysts point to momentum but caution on sustainability absent competing bids or further fundamentals. Zacks coverage of Penumbra price move
• Negative Sentiment: Needham downgraded Penumbra from Buy to Hold — a straightforward analyst reaction that could weigh on sentiment and aftermarket buying absent a higher competing bid. Penumbra downgraded at Needham
• Negative Sentiment: Multiple shareholder law firms (Kahn Swick & Foti, Halper Sadeh, Ademi, Brodsky & Smith, others) have opened investigations and class-action alerts alleging the sale price/process may be unfair — litigation or legal challenges could delay the deal, lead to renegotiation, or increase transaction costs. Kahn Swick & Foti investor alert on Penumbra sale

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Needham & Company LLC cut Penumbra from a “buy” rating to a “hold” rating in a report on Friday. Leerink Partnrs downgraded shares of Penumbra from a “strong-buy” rating to a “hold” rating in a research report on Thursday. BTIG Research lowered shares of Penumbra from a “buy” rating to a “neutral” rating and set a $349.00 target price on the stock. in a research note on Thursday. Baird R W cut shares of Penumbra from a “strong-buy” rating to a “hold” rating in a research report on Friday. Finally, Truist Financial lowered shares of Penumbra from a “buy” rating to a “hold” rating and increased their price objective for the company from $370.00 to $374.00 in a report on Friday. Seven equities research analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company. According to MarketBeat, Penumbra currently has a consensus rating of “Hold” and a consensus target price of $355.88.

Penumbra Stock Up 0.1%

The business’s 50-day moving average is $303.54 and its two-hundred day moving average is $269.52. The firm has a market capitalization of $13.74 billion, a price-to-earnings ratio of 83.95, a P/E/G ratio of 2.14 and a beta of 0.71. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.18 and a current ratio of 6.73.

Penumbra (NYSE:PEN) last issued its earnings results on Wednesday, November 5th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.90 by $0.07. The firm had revenue of $354.69 million during the quarter, compared to the consensus estimate of $340.77 million. Penumbra had a net margin of 12.30% and a return on equity of 11.35%. The business’s quarterly revenue was up 17.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.85 earnings per share. On average, equities analysts anticipate that Penumbra, Inc. will post 3.67 earnings per share for the current year.

Insiders Place Their Bets

In related news, EVP Johanna Roberts sold 300 shares of the stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $300.13, for a total transaction of $90,039.00. Following the completion of the sale, the executive vice president directly owned 63,836 shares of the company’s stock, valued at approximately $19,159,098.68. This represents a 0.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Harpreet Grewal sold 186 shares of the firm’s stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $312.64, for a total transaction of $58,151.04. Following the sale, the director owned 8,230 shares in the company, valued at $2,573,027.20. This trade represents a 2.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 34,144 shares of company stock worth $10,260,127. 4.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Penumbra

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Mather Group LLC. bought a new stake in shares of Penumbra in the third quarter valued at about $25,000. Newbridge Financial Services Group Inc. acquired a new stake in Penumbra in the 2nd quarter valued at approximately $30,000. Rothschild Investment LLC acquired a new stake in Penumbra in the 3rd quarter valued at approximately $40,000. Parkside Financial Bank & Trust lifted its stake in Penumbra by 70.2% in the 2nd quarter. Parkside Financial Bank & Trust now owns 160 shares of the company’s stock valued at $41,000 after acquiring an additional 66 shares in the last quarter. Finally, Covestor Ltd boosted its position in Penumbra by 53.0% during the 3rd quarter. Covestor Ltd now owns 179 shares of the company’s stock worth $46,000 after acquiring an additional 62 shares during the last quarter. 88.88% of the stock is currently owned by institutional investors and hedge funds.

Penumbra Company Profile

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.